Potential Therapeutic Options for COVID-19

Overview

Journal Infect Microbes Dis

Date 2024 Apr 17

PMID 38630098

Authors

Xiaoqin Zheng

Lanjuan Li

Affiliations

Soon will be listed here.

Abstract

The recently emerged coronavirus disease 2019 (COVID-19) has rapidly evolved into a pandemic with over 10 million infections and over 500 thousand deaths. There are currently no effective therapies or vaccines available to protect against this coronavirus infection. In this review, we discuss potential therapeutic options for COVID-19 based on the available information from previous research on severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Substantial efforts are underway to discover new therapeutic agents for COVID-19, including the repurposing of existing agents and the development of novel agents that specifically target SARS-coronavirus 2 (SARS-CoV-2) or host factors. Through the screening of compound libraries, various classes of drugs, such as ribavirin, remdesivir, lopinavir/ritonavir, and hydroxychloroquine have been identified as potential therapeutic candidates against COVID-19. Novel antiviral drugs for SARS-coronavirus 2 are being developed to target viral enzymes or functional proteins, as well as host factors or cell signaling pathways.

Citing Articles

Nicotinamide: Oversight of Metabolic Dysfunction Through SIRT1, mTOR, and Clock Genes.

Maiese K Curr Neurovasc Res. 2020; 17(5):765-783.

PMID: 33183203 PMC: 7914159. DOI: 10.2174/1567202617999201111195232.

References

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

Rosenberg E, Dufort E, Udo T, Wilberschied L, Kumar J, Tesoriero J . Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020; 323(24):2493-2502. PMC: 7215635. DOI: 10.1001/jama.2020.8630. View

Huentelman M, Zubcevic J, Hernandez Prada J, Xiao X, Dimitrov D, Raizada M . Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 2004; 44(6):903-6. DOI: 10.1161/01.HYP.0000146120.29648.36. View

Elfiky A . Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020; 253:117592. PMC: 7102646. DOI: 10.1016/j.lfs.2020.117592. View

Ko J, Seok H, Cho S, Ha Y, Baek J, Kim S . Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018; 23(7):617-622. DOI: 10.3851/IMP3243. View

Ou X, Liu Y, Lei X, Li P, Mi D, Ren L . Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020; 11(1):1620. PMC: 7100515. DOI: 10.1038/s41467-020-15562-9. View

Pfefferle S, Schopf J, Kogl M, Friedel C, Muller M, Carbajo-Lozoya J . The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog. 2011; 7(10):e1002331. PMC: 3203193. DOI: 10.1371/journal.ppat.1002331. View

Ge Y, Tian T, Huang S, Wan F, Li J, Li S . An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. Signal Transduct Target Ther. 2021; 6(1):165. PMC: 8065335. DOI: 10.1038/s41392-021-00568-6. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

10.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

11.

Spanakis N, Tsiodras S, Haagmans B, Raj V, Pontikis K, Koutsoukou A . Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014; 44(6):528-32. PMC: 7127532. DOI: 10.1016/j.ijantimicag.2014.07.026. View

12.

Kuri T, Zhang X, Habjan M, Martinez-Sobrido L, Garcia-Sastre A, Yuan Z . Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. J Gen Virol. 2009; 90(Pt 11):2686-2694. PMC: 2888313. DOI: 10.1099/vir.0.013599-0. View

13.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

14.

Sanche S, Lin Y, Xu C, Romero-Severson E, Hengartner N, Ke R . High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2020; 26(7):1470-1477. PMC: 7323562. DOI: 10.3201/eid2607.200282. View

15.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

16.

Chan J, Lau S, To K, Cheng V, Woo P, Yuen K . Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015; 28(2):465-522. PMC: 4402954. DOI: 10.1128/CMR.00102-14. View

17.

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

18.

Pfaender S, Mar K, Michailidis E, Kratzel A, Boys I, Vkovski P . LY6E impairs coronavirus fusion and confers immune control of viral disease. Nat Microbiol. 2020; 5(11):1330-1339. PMC: 7916999. DOI: 10.1038/s41564-020-0769-y. View

19.

Han D, Penn-Nicholson A, Cho M . Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology. 2006; 350(1):15-25. PMC: 7111894. DOI: 10.1016/j.virol.2006.01.029. View

20.

Adedeji A, Singh K, Calcaterra N, DeDiego M, Enjuanes L, Weiss S . Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother. 2012; 56(9):4718-28. PMC: 3421890. DOI: 10.1128/AAC.00957-12. View